Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Sanofi","sponsor":"Fidia Farmaceutici Spa","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanofi Continues Streamlining of Established Products with Sale of Anti-Inflammatory Drugs to Fidia Farmaceutici","therapeuticArea":"Immunology","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"}]

Sanofi

Contact Supplier

Pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Contact Supplier

Contact Supplier

Digital Content

Sanofi Continues Streamlining of Established Products with Sale of Anti-Inflammatory Drugs to Fidia Farmaceutici

Details:

The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets.

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Fidia Farmaceutici Spa

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Divestment March 23, 2021

Sanofi Company Banner

BioProcess International 2022

Not Confirmed

envelop

Contact Supplier

POST ENQUIRY